Advanced Rcc With Clear Cell Component clinical trials

Explore recruiting advanced rcc with clear cell component clinical trials.

Also recruiting in Europe

Advanced Rcc With Clear Cell Component trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Austria, Ireland, Belgium, Romania, Poland, Germany +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Advanced Rcc With Clear Cell Component trials by city

Advanced Rcc With Clear Cell Component in Toronto Advanced Rcc With Clear Cell Component in Vancouver Advanced Rcc With Clear Cell Component in Montreal Advanced Rcc With Clear Cell Component in Calgary Advanced Rcc With Clear Cell Component in Edmonton Advanced Rcc With Clear Cell Component in Ottawa Advanced Rcc With Clear Cell Component in Winnipeg Advanced Rcc With Clear Cell Component in Quebec City Advanced Rcc With Clear Cell Component in Hamilton Advanced Rcc With Clear Cell Component in Kitchener Advanced Rcc With Clear Cell Component in London Advanced Rcc With Clear Cell Component in Halifax Advanced Rcc With Clear Cell Component in New York Advanced Rcc With Clear Cell Component in Los Angeles Advanced Rcc With Clear Cell Component in Chicago Advanced Rcc With Clear Cell Component in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease